Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 95,900 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 95,900 shares of the firm’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $21.02, for a total transaction of $2,015,818.00. Following the completion of the transaction, the director directly owned 1,086,063 shares of the company’s stock, valued at approximately $22,829,044.26. The trade was a 8.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Trading Up 1.6%

Dyne Therapeutics stock opened at $20.94 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. Dyne Therapeutics, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $25.00. The stock has a market cap of $3.46 billion, a P/E ratio of -6.50 and a beta of 1.09. The firm’s fifty day moving average price is $18.45 and its 200-day moving average price is $18.11.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period in the prior year, the business posted ($1.05) EPS. Equities research analysts forecast that Dyne Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DYN. Evercore set a $33.00 price target on Dyne Therapeutics in a research report on Friday, May 15th. Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 20th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. HC Wainwright dropped their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Finally, TD Cowen started coverage on shares of Dyne Therapeutics in a research note on Friday. They issued a “buy” rating for the company. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $34.17.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Hilton Head Capital Partners LLC bought a new position in shares of Dyne Therapeutics during the 1st quarter valued at about $26,000. Strs Ohio bought a new stake in Dyne Therapeutics in the 4th quarter worth approximately $51,000. Aster Capital Management DIFC Ltd purchased a new stake in Dyne Therapeutics in the fourth quarter worth approximately $84,000. Steward Partners Investment Advisory LLC grew its position in Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Dyne Therapeutics by 275.1% during the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after acquiring an additional 7,697 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.